Related Experiment Videos
TP53-binding protein variants and breast cancer risk: a case-control study
Bernd Frank1, Kari Hemminki, Justo Lorenzo Bermejo
1Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. b.frank@dkfz.de
Breast Cancer Research : BCR
|July 1, 2005
Summary
Single nucleotide polymorphisms in 53BP1 (TP53-binding protein) did not significantly impact breast cancer risk. A novel 6bp deletion in 53BP1 showed a non-significant inverse association with breast cancer risk.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- The TP53-binding protein (53BP1) is crucial for DNA damage signaling and TP53 transcriptional activation.
- Genetic variations in TP53, ATM, and CHEK2 are linked to cancer predisposition.
- This study investigates the role of specific 53BP1 variants in breast cancer risk.
Purpose of the Study:
- To evaluate the association between 53BP1 single nucleotide polymorphisms (D353E, G412S, K1136Q) and breast cancer risk.
- To assess the impact of a novel 53BP1 6bp deletion (1347_1352delTATCCC) on breast cancer susceptibility.
Main Methods:
- Genotyping of 53BP1 variants (D353E, G412S, K1136Q, 1347_1352delTATCCC) using allelic discrimination.
- Analysis of variant frequencies in 353 breast cancer patients and 960 control individuals.
Main Results:
- No significant association was found between 53BP1 D353E, G412S, or K1136Q and breast cancer risk.
- The 53BP1 1347_1352delTATCCC variant exhibited a non-significant inverse association with breast cancer risk (OR = 0.61, P = 0.34).
Conclusions:
- The findings question the proposed role of 53BP1 D353E, G412S, and K1136Q in breast cancer risk.
- Larger cohorts are needed to confirm the potential influence of the 53BP1 6bp deletion on breast cancer.
- Further research on the functional impact and cancer risk association of this deletion is warranted.